FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070528305> ?p ?o ?g. }

• W2070528305 endingPage "1001" @default.
• W2070528305 startingPage "994" @default.
• W2070528305 abstract "Introduction:Gaining a higher response rate (RR) has usually been determined as a primary end point in phase II trials evaluating the efficacy of new molecular targeted drugs. However, a relationship between clinical response and survival benefit has not been well studied in the patients treated with molecular targeted agents.Methods:Prospective trials of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) monotherapy in non-small cell lung cancer were extracted from MEDLINE, EMBASE, and the annual meetings in 2007 of the American Society of Clinical Oncology, European Cancer Conference, and World Conference on Lung Cancer.Correlation between clinical response and survival was examined using linear regression analysis. We also tried to compare the significance of RR as surrogate markers for survival with that of disease control rate (DCR) by calculating the area under their receiver operating characteristic (ROC) curves.Results:We identified 24 phase II trials and 4 phase III trials with a total of 6171 patients and 30 treatment arms, including 22 arms for the gefitinib group and 8 arms for the erlotinib group. Both RR and DCR strongly correlated with median survival time (MST; p < 0.0001 and p = 0.003, respectively). In an ROC analysis, the area under the ROC curve predicting MST prolongation by RR was 0.918, which was higher than the area under the ROC curve by DCR.Conclusions:We found a significant relationship between RR and MST in clinical trials with EGFR-TKIs. RR could be an independent surrogate marker for MST in the current response criteria in the clinical trials of EGFR-TKIs." @default.
• W2070528305 created "2016-06-24" @default.
• W2070528305 creator A5000971952 @default.
• W2070528305 creator A5020676351 @default.
• W2070528305 creator A5044361715 @default.
• W2070528305 creator A5044823537 @default.
• W2070528305 creator A5052923575 @default.
• W2070528305 creator A5054386489 @default.
• W2070528305 creator A5063817865 @default.
• W2070528305 creator A5070460443 @default.
• W2070528305 creator A5070574455 @default.
• W2070528305 creator A5084771205 @default.
• W2070528305 date "2009-08-01" @default.
• W2070528305 modified "2023-10-16" @default.
• W2070528305 title "Response Rate Is Associated with Prolonged Survival in Patients with Advanced Non-small Cell Lung Cancer Treated with Gefitinib or Erlotinib" @default.
• W2070528305 cites W1980791428 @default.
• W2070528305 cites W1989146386 @default.
• W2070528305 cites W2015378165 @default.
• W2070528305 cites W2022035446 @default.
• W2070528305 cites W2032573089 @default.
• W2070528305 cites W2041035291 @default.
• W2070528305 cites W2046238840 @default.
• W2070528305 cites W2049484790 @default.
• W2070528305 cites W2058592399 @default.
• W2070528305 cites W2058972335 @default.
• W2070528305 cites W2073693702 @default.
• W2070528305 cites W2077042878 @default.
• W2070528305 cites W2103363123 @default.
• W2070528305 cites W2106585301 @default.
• W2070528305 cites W2114447587 @default.
• W2070528305 cites W2118135682 @default.
• W2070528305 cites W2119248047 @default.
• W2070528305 cites W2120718661 @default.
• W2070528305 cites W2121612336 @default.
• W2070528305 cites W2122553809 @default.
• W2070528305 cites W2123532766 @default.
• W2070528305 cites W2129455899 @default.
• W2070528305 cites W2134373354 @default.
• W2070528305 cites W2136618123 @default.
• W2070528305 cites W2138297714 @default.
• W2070528305 cites W2139343412 @default.
• W2070528305 cites W2140775102 @default.
• W2070528305 cites W2142850084 @default.
• W2070528305 cites W2142865455 @default.
• W2070528305 cites W2143171062 @default.
• W2070528305 cites W2146404049 @default.
• W2070528305 cites W2149469912 @default.
• W2070528305 cites W2153477391 @default.
• W2070528305 cites W2153942353 @default.
• W2070528305 cites W2154008785 @default.
• W2070528305 cites W2160403329 @default.
• W2070528305 cites W2161664263 @default.
• W2070528305 cites W2162638402 @default.
• W2070528305 cites W2519926137 @default.
• W2070528305 cites W2520449271 @default.
• W2070528305 doi "https://doi.org/10.1097/jto.0b013e3181a94a2f" @default.
• W2070528305 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19633474" @default.
• W2070528305 hasPublicationYear "2009" @default.
• W2070528305 type Work @default.
• W2070528305 sameAs 2070528305 @default.
• W2070528305 citedByCount "40" @default.
• W2070528305 countsByYear W20705283052012 @default.
• W2070528305 countsByYear W20705283052013 @default.
• W2070528305 countsByYear W20705283052014 @default.
• W2070528305 countsByYear W20705283052015 @default.
• W2070528305 countsByYear W20705283052016 @default.
• W2070528305 countsByYear W20705283052017 @default.
• W2070528305 countsByYear W20705283052018 @default.
• W2070528305 countsByYear W20705283052020 @default.
• W2070528305 countsByYear W20705283052021 @default.
• W2070528305 countsByYear W20705283052022 @default.
• W2070528305 crossrefType "journal-article" @default.
• W2070528305 hasAuthorship W2070528305A5000971952 @default.
• W2070528305 hasAuthorship W2070528305A5020676351 @default.
• W2070528305 hasAuthorship W2070528305A5044361715 @default.
• W2070528305 hasAuthorship W2070528305A5044823537 @default.
• W2070528305 hasAuthorship W2070528305A5052923575 @default.
• W2070528305 hasAuthorship W2070528305A5054386489 @default.
• W2070528305 hasAuthorship W2070528305A5063817865 @default.
• W2070528305 hasAuthorship W2070528305A5070460443 @default.
• W2070528305 hasAuthorship W2070528305A5070574455 @default.
• W2070528305 hasAuthorship W2070528305A5084771205 @default.
• W2070528305 hasBestOaLocation W20705283051 @default.
• W2070528305 hasConcept C121608353 @default.
• W2070528305 hasConcept C126322002 @default.
• W2070528305 hasConcept C141341695 @default.
• W2070528305 hasConcept C143998085 @default.
• W2070528305 hasConcept C203092338 @default.
• W2070528305 hasConcept C2776256026 @default.
• W2070528305 hasConcept C2778087573 @default.
• W2070528305 hasConcept C2779438470 @default.
• W2070528305 hasConcept C2780580887 @default.
• W2070528305 hasConcept C2909325608 @default.
• W2070528305 hasConcept C535046627 @default.
• W2070528305 hasConcept C58471807 @default.
• W2070528305 hasConcept C71924100 @default.
• W2070528305 hasConceptScore W2070528305C121608353 @default.
• W2070528305 hasConceptScore W2070528305C126322002 @default.

• next